BF 389

Drug Profile

BF 389

Alternative Names: Biofor 389

Latest Information Update: 01 Jun 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scherer Healthcare
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oxazines
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatic disorders

Most Recent Events

  • 01 Jun 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 09 Jul 1998 Biofor is now part of Scherer Healthcare
  • 15 Aug 1995 Phase-I clinical trials for Rheumatic disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top